The China CardioMyopathy Registry Study
CHINA-CM
1 other identifier
observational
5,000
1 country
1
Brief Summary
Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, so it has a huge psychological and economic burden on family members. Studying the clinical characteristics of patients with cardiomyopathy is helpful for further diagnosis, treatment and management, which has important clinical and social significance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 10, 2023
CompletedFirst Posted
Study publicly available on registry
May 23, 2023
CompletedStudy Start
First participant enrolled
July 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2027
ExpectedMay 23, 2023
May 1, 2023
2 years
May 10, 2023
May 13, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
number of participants with cardiovascular deaths
including sudden cardiac death and deaths due to heart failure and stroke
an average of 1 year
Secondary Outcomes (4)
number of participants with heart failure
an average of 1 year
number of participants with stroke
an average of 1 year
number of participants with myocardial infarction
an average of 1 year
number of participants with all-cause deaths
an average of 1 year
Eligibility Criteria
Patients hospitalized with cardiomyopathy as the primary discharge diagnosis are recruited prospectively from multiple centers in China between July 1, 2023 and June 30, 2025.
You may qualify if:
- Patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.
You may not qualify if:
- Patients who refuse to sign the informed consent or decline follow-up.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fuwai hospital
Beijing, Beijing Municipality, 100037, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator, Clinical Professor
Study Record Dates
First Submitted
May 10, 2023
First Posted
May 23, 2023
Study Start
July 1, 2023
Primary Completion
June 30, 2025
Study Completion (Estimated)
June 30, 2027
Last Updated
May 23, 2023
Record last verified: 2023-05